Asset Details
Do you wish to reserve the book?
Bystander immunotherapy as a strategy to control allergen-driven airway inflammation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bystander immunotherapy as a strategy to control allergen-driven airway inflammation
Do you wish to request the book?
Bystander immunotherapy as a strategy to control allergen-driven airway inflammation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Bystander immunotherapy as a strategy to control allergen-driven airway inflammation
2015
Overview
Allergic asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness (AHR), lung infiltration of Th2 cells, and high levels of IgE. To date, allergen-specific immunotherapy (SIT) is the only treatment that effectively alleviates clinical symptoms and has a long-term effect after termination. Unfortunately, SIT is unsuitable for plurisensitized patients, and highly immunogenic allergens cannot be used. To overcome these hurdles, we sought to induce regulatory CD4+ T cells (Treg) specific to an exogenous antigen that could be later activated as needed in vivo to control allergic responses. We have established an experimental approach in which mice tolerized to ovalbumin (OVA) were sensitized to the Leishmania homolog of receptors for activated c kinase (LACK) antigen, and subsequently challenged with aerosols of LACK alone or LACK and OVA together. Upon OVA administration, AHR and allergic airway responses were strongly reduced. OVA-induced suppression was mediated by CD25+ Treg, required CTLA-4 and ICOS signaling and resulted in decreased numbers of migrating airway dendritic cells leading to a strong impairment in the proliferation of allergen-specific Th2 cells. Therefore, inducing Treg specific to a therapeutic antigen that could be further activated in vivo may represent a safe and novel curative approach for allergic asthma.
Publisher
Elsevier Inc,Nature Publishing Group US,Elsevier Limited,Nature Pub. Group
Subject
/ Allergens - administration & dosage
/ Animals
/ Antigens, Protozoan - immunology
/ Biomedical and Life Sciences
/ Bronchoalveolar Lavage Fluid - immunology
/ Desensitization, Immunologic - methods
/ Immunoglobulin E - immunology
/ Inducible T-Cell Co-Stimulator Protein - metabolism
/ Interleukin-2 Receptor alpha Subunit - metabolism
/ Lymphocyte Activation - immunology
/ Mice
/ Ovalbumin - administration & dosage
/ Protozoan Proteins - immunology
/ Respiratory Hypersensitivity - immunology
/ Respiratory Hypersensitivity - metabolism
/ Respiratory Hypersensitivity - therapy
/ T-Lymphocytes, Regulatory - immunology
